Profile and Management of Toxicity of Selinexor and Belantamab Mafodotin for the Treatment of Triple Class Refractory Multiple Myeloma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Profile and Management of Toxicity of Selinexor and Belantamab Mafodotin for the Treatment of Triple Class Refractory Multiple Myeloma

Published:2021-07 Issue: Volume:Volume 12 Page:529-550
ISSN:1179-2736
Container-title:Journal of Blood Medicine
language:en
Short-container-title:JBM

Author:

Neupane Karun^ORCID,Wahab Ahsan,Masood Adeel^ORCID,Faraz Tehniat^ORCID,Bahram Saman,Ehsan Hamid^ORCID,Hannan Abdul,Anwer Faiz

Publisher

Informa UK Limited

Subject

Hematology

Reference40 articles.

1. Cancer statistics, 2020

2. Safety and efficacy of selinexor in relapsed or refractory multiple myeloma and Waldenstrom macroglobulinemia

3. Selinexor plus low-dose bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma

4. Selinexor: First Global Approval

5. Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Rediscovering hemostasis abnormalities in multiple myeloma: The new era;Heliyon;2024-07

2. Efficacy of Selinexor in Relapsed/Refractory Multiple Myeloma (RRMM) Patients with del17p and Other High-Risk Abnormalities (A Retrospective Single-Center Study);Life;2024-03-14

3. Efficacy and safety of selinexor-based regimens for relapsed/refractory multiple myeloma: a systematic review of literature;Annals of Hematology;2022-10-10

4. The molecular mechanism and challenge of targeting XPO1 in treatment of relapsed and refractory myeloma;Translational Oncology;2022-08

5. HibeRNAtion: HIV-1 RNA Metabolism and Viral Latency;Frontiers in Cellular and Infection Microbiology;2022-06-14

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3